| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 |
| filingDate |
2015-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88f287da9ec6a6b8a2257daad1465978
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcf13e916283eb0f8b1dac9fb3935029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049a501084e03786603334db2c17f6ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32500b5c659d41ae18a9ba779f930f63 |
| publicationDate |
2019-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2684906-C2 |
| titleOfInvention |
AMIDE CONNECTIONS |
| abstract |
The invention relates to 4 - [(1S) -1 - ({[4-bromo-1- (isoquinolin-3-ylmethyl) -3-methyl-1H-pyrazol-5-yl] carbonyl} amino) ethyl] benzoic acid or its pharmaceutically acceptable salt, preferably to the methanesulfonate salt, and most preferably to the crystalline methanesulfonate salt of the above compound. The invention provides a compound that has an antagonistic effect on the EP4 receptor. This compound and its pharmaceutically acceptable salts can be used as an active ingredient of a pharmaceutical composition for the prevention and / or treatment of various diseases associated with EP-4, such as chronic renal failure and / or diabetic nephropathy. 6 n. and 5 hp f-ly, 12, etc. |
| priorityDate |
2014-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |